Synthego
US-based Synthego Corp. provides software solutions for biological research, primarily serving California.
Founded
2012US-based Synthego Corp. provides software solutions for biological research, primarily serving California.
Founded in Menlo Park, California, Synthego is a biotechnology company focused on making CRISPR gene editing more accessible and efficient. The company's core mission is to accelerate the pace of scientific discovery by providing high-quality, reliable tools for genome engineering. Synthego offers a range of products, including multi-guide RNA kits and custom-made edited cells, designed to simplify and streamline the CRISPR process for researchers. Their market focus includes academic institutions, pharmaceutical companies, and biotech firms primarily in California but with a growing global presence.
Notable affiliated individuals include co-founders Paul and Michael Dabrowski, who have backgrounds in engineering and software development. Synthego has attracted significant investment from prominent venture capital firms such as 8VC and Founders Fund. Key achievements include the development of automated platforms for RNA synthesis and cell engineering, which have significantly reduced the time and cost associated with CRISPR research. Overall, Synthego has made a substantial impact on the field of genetic engineering by democratizing access to advanced genome editing technologies.
Companies similar to Synthego include Inscripta, Acrigen Biosciences, Switchback Systems and Twist Bioscience.
Synthego was founded in 2012.
Synthego's headquarters is located in Redwood City, CA, US.
Synthego's most recent funding round was for $200M (USD) in February 2022.
As of Feb 17, 2022, Synthego has disclosed funding of $459.7M (USD). Undisclosed round amounts are excluded.
Synthego has 322 employees as of Feb 5, 2024.
Twist Bioscience
